ES2689776T3 - Compuestos para el uso para potenciar la coagulación - Google Patents

Compuestos para el uso para potenciar la coagulación Download PDF

Info

Publication number
ES2689776T3
ES2689776T3 ES12758914.1T ES12758914T ES2689776T3 ES 2689776 T3 ES2689776 T3 ES 2689776T3 ES 12758914 T ES12758914 T ES 12758914T ES 2689776 T3 ES2689776 T3 ES 2689776T3
Authority
ES
Spain
Prior art keywords
inhibitor
bleeding
plasma
thrombin
rsl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12758914.1T
Other languages
English (en)
Spanish (es)
Inventor
Cornelis Erik Hack
Cafer YILDIZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
Original Assignee
UMC Utrecht Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV filed Critical UMC Utrecht Holding BV
Application granted granted Critical
Publication of ES2689776T3 publication Critical patent/ES2689776T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
ES12758914.1T 2011-08-25 2012-08-24 Compuestos para el uso para potenciar la coagulación Active ES2689776T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527140P 2011-08-25 2011-08-25
US201161527140P 2011-08-25
PCT/NL2012/050581 WO2013028070A2 (en) 2011-08-25 2012-08-24 Compounds for use in boosting coagulation

Publications (1)

Publication Number Publication Date
ES2689776T3 true ES2689776T3 (es) 2018-11-15

Family

ID=46845975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12758914.1T Active ES2689776T3 (es) 2011-08-25 2012-08-24 Compuestos para el uso para potenciar la coagulación

Country Status (14)

Country Link
US (1) US20140356377A1 (cg-RX-API-DMAC10.html)
EP (1) EP2747776B1 (cg-RX-API-DMAC10.html)
JP (2) JP6198277B2 (cg-RX-API-DMAC10.html)
CN (1) CN103930129A (cg-RX-API-DMAC10.html)
AU (1) AU2012299524B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014004297B1 (cg-RX-API-DMAC10.html)
CA (1) CA2846494C (cg-RX-API-DMAC10.html)
CY (1) CY1120688T1 (cg-RX-API-DMAC10.html)
DK (1) DK2747776T3 (cg-RX-API-DMAC10.html)
ES (1) ES2689776T3 (cg-RX-API-DMAC10.html)
HU (1) HUE039590T2 (cg-RX-API-DMAC10.html)
PL (1) PL2747776T3 (cg-RX-API-DMAC10.html)
PT (1) PT2747776T (cg-RX-API-DMAC10.html)
WO (1) WO2013028070A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150127202A (ko) 2013-03-14 2015-11-16 바이엘 헬스케어 엘엘씨 헤파린과 복합체화된 항트롬빈 베타에 대한 모노클로날 항체
EP3904519A1 (en) 2014-10-30 2021-11-03 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
WO2017158176A1 (en) * 2016-03-18 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
JP6883899B1 (ja) * 2020-12-07 2021-06-09 株式会社血栓トランスレーショナルリサーチラボ 血液凝固検査試薬、および血液凝固検査方法
PL440675A1 (pl) * 2022-03-17 2023-09-18 Politechnika Wrocławska Związki do równoległego wykrywania i hamowania proteaz szlaku krzepnięcia - APC, trombiny, czynnika Xa i czynnika XIa w ludzkim osoczu

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748913A (en) * 1904-01-05 Fo model
WO2009013251A1 (en) * 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
DE102011081871A1 (de) * 2011-08-31 2013-02-28 Henkel Ag & Co. Kgaa Oxazolidine zur Fehlgeruchsbekämpfung

Also Published As

Publication number Publication date
DK2747776T3 (en) 2018-09-17
US20140356377A1 (en) 2014-12-04
CA2846494C (en) 2020-10-20
WO2013028070A2 (en) 2013-02-28
AU2012299524B2 (en) 2017-03-23
EP2747776B1 (en) 2018-07-11
BR112014004297A2 (pt) 2017-03-28
JP2017186340A (ja) 2017-10-12
CA2846494A1 (en) 2013-02-28
PT2747776T (pt) 2018-10-31
AU2012299524A1 (en) 2014-03-13
JP6198277B2 (ja) 2017-09-20
PL2747776T3 (pl) 2019-03-29
CN103930129A (zh) 2014-07-16
BR112014004297B1 (pt) 2021-12-14
WO2013028070A3 (en) 2013-04-18
HUE039590T2 (hu) 2019-01-28
JP2014529606A (ja) 2014-11-13
EP2747776A2 (en) 2014-07-02
CY1120688T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
CA2846494C (en) Compounds for use in boosting coagulation
AU2008323947B2 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
ES2844189T3 (es) Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
ES2605801T3 (es) Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
AU2014301041A1 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
ES2283308T3 (es) Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.
ES2119165T5 (es) Nueva actividad de cofactor anticoagulante.
Thomassen et al. Tissue factor‐independent inhibition of thrombin generation by tissue factor pathway inhibitor‐α
ES2285734T3 (es) Multimerasa purificada.
ES2277597T3 (es) Agentes antitromboticos.
CN115835880A (zh) Adamts13蛋白质变体及其用途
JP2022513332A (ja) プロテインsレベルの決定方法
JP7635223B2 (ja) 好中球細胞外トラップに関連する線維素溶解不全の診断方法
Lindo Jr Characterization of an alpha2-antiplasmin antibody
WO2012004437A1 (es) Nuevo inhibidor de serina proteasa y su uso
CA2488968A1 (en) Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy
McAiney Characterization of the I4399M Variant of Apolipoprotein (a): Implications for Altered Prothrombotic Properties of Lipoprotein (a)
Wu Characterization of TAFI activation by the thrombin-thrombomodulin complex
Björkqvist Mechanism and Therapy of Hereditary Angioedema Type III and Role of the Contact System in Inflammatory Diseases
AU2020394374A1 (en) CELA-1 inhibition for treatment of lung disease
CA3006175A1 (en) Recombinant serine proteases